Navigation Links
Questcor Reports 2010 Financial Results
Date:2/23/2011

. Questcor anticipates that this new tax law will result in a significantly reduced California tax liability in future periods.
  • Stock-based compensation expense.
  • Other non-cash expenses, including depreciation and amortization.

  • Non-GAAP net income for the quarter ended December 31, 2009 was $9.0 million, or $0.14 per diluted common share.  On a GAAP basis, net income for the quarter ended December 31, 2010 was $6.4 million, or $0.10 per diluted common share, compared to $8.4 million and $0.13 per diluted common share for the fourth quarter of 2009.  The reconciliation between GAAP and Non-GAAP net income is provided with the financial tables included with this release.

    The Company believes it is important to share these non-GAAP financial measures with shareholders as they better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net income should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP net income.

    Cash As of February 18, 2011, Questcor's cash, cash equivalents and short-term investments totaled $127 million.  As of December 31, 2010, Questcor had 62.4 million shares of common stock outstanding.

    Acthar Sales for MS, IS and NS During the fourth quarter of 2010, Questcor shipped 1,680 vials of Acthar compared to 1,626 vials in the fourth quarter of 2009.  For the full year of 2010, Questcor shipped 6,696 vials of Acthar compared to 5,973 vials in 2009.  Because Acthar prescriptions are filled at specialty pharmacies, the Company does not receive complete information regarding either the number of prescriptions or the number of vials by therapeutic area for all of the patients being treated with Acthar.  Howeve
    '/>"/>

    SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
    2. Questcor Pharmaceuticals Reports Strong Finish to 2010
    3. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
    4. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    5. Questcor to Present at the Maxim Group Growth Conference
    6. Questcor Reports Third Quarter 2010 Results
    7. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
    8. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
    9. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
    10. Questcor to Present at UBS Global Life Sciences Conference
    11. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
    (Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
    (Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
    Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
    (Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
    (Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
    (Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
    (Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
    (Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
    Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
    ... validity of Purdue patents; Receives limited license rights ... ST. LOUIS, June 9 KV Pharmaceutical Company (NYSE: ... it has entered into a settlement agreement with Purdue Pharma ... lawsuit between the two companies. Under the terms of ...
    ... early in the course of disease is the best approach ... acute myeloid leukemia (AML), according to a new analysis of ... published in the June 10 issue of the Journal ... Cancer Institute and other institutions, provide new guidelines for treatment ...
    ... , WASHINGTON, June 9 The "Blue Dog Coalition," a ... oppose a strong public option to for-profit health insurers, took ... insurance and drug industries according to Consumer Watchdog. , ... Landrieu (D-LA) now opposes the public option. Landrieu received ...
    ... expert says, , TUESDAY, June 9 (HealthDay News) -- ... women as their pregnancy progresses, a new Brazilian study ... to 80 percent of moms-to-be suffering heartburn, stomach pain ... worsen over time, and women who avoid taking medicine ...
    ... PEMBROKE, Bermuda, June 9 Allied World Assurance,Company (U.S.) ... Ltd (NYSE: AWH ), today announced an ... in the United States. The,complimentary service, called "Strategic Response(SM)," ... resources in the,event of a catastrophe. , ...
    ... New Dialysis Patients Making a Difference in Cutting Patient Mortality ... (NYSE: DVA ), a leading provider of kidney ... today commended Kidney Care Partners for launching the Performance Excellence ... Partners - a coalition of patient advocates, dialysis professionals, care ...
    Cached Medicine News:Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 2Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 3Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 4Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 5Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 6Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 3Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 4Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
    Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right. Most popular size or model....
    Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
    Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
    Delicate # 4...
    Medicine Products: